View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
TUESDAY, March 22 (HealthDay News) -- Dalteparin, a low-molecular-weight heparin, does not appear any more effective in lowering the incidence of proximal deep-vein thrombosis than unfractionated heparin, according to research published online March 22 in The New England Journal of Medicine.
Deborah Cook, M.D., of McMaster University in Hamilton, Canada, and colleagues randomly assigned 3,764 critically ill patients to either subcutaneous dalteparin plus placebo or unfractionated heparin during their time in the intensive care unit to compare the two therapies for prevention of venous thromboembolism.
The researchers found no significant difference between the two groups in terms of the rate of proximal leg deep-vein thrombosis. The dalteparin group had a significantly lower proportion of patients with pulmonary emboli (hazard ratio 0.51), but there was no significant difference between the groups in major bleeding or in-hospital death.
"Among critically ill patients, dalteparin was not superior to unfractionated heparin in decreasing the incidence of proximal deep-vein thrombosis," the authors write.
Three authors disclosed financial relationships with pharmaceutical companies.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top